

SUPPORT FOR THE AMENDMENTS

Claims 1-49, 65, and 67-86 were previously canceled.

Claim 52 is amended herein.

Claims 50, 51, 54-56, 61, and 64 have been amended.

Support for the amendment of Claims 50, 51, 54-56, 61, and 64 is provided by the corresponding claims as previously presented, as well as the original claims and specification as filed.


No new matter has been added by the present amendments.

REMARKS


Claims 50, 51, 53-64, 66, and 87-96 are pending in the present application.

The rejections of Claims 50 and 66 under 35 U.S.C. §102(b) over Caplus Abstract 1962:436041 and over Caplus Abstract 1962:436039 are obviated by amendment.

The Examiner cites Caplus Abstract 1962:436041, which is a compound of the



The Examiner also cites Caplus Abstract 1962:436039, which is a compound of the



Applicants have amended the claims to specifically exclude these compound by amending the definition of group A in claim 50 to remove “carbocyclic moiety”. Thus, Caplus Abstract 1962:436041 and Caplus Abstract 1962:436039 do not disclose a compound within the scope of the claims as amended herein.

Withdrawal of these grounds of rejection is requested.

With respect to the non-elected method claims, Applicants remind the Examiner of MPEP §821.04 and the eligibility of rejoinder. Upon a finding of allowability of the elected product claims, Applicants respectfully request rejoinder of the withdrawn process claims that depend therefrom.

Applicants submit that the present application is now in condition for allowance.

Early notification of such action is earnestly solicited.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, L.L.P.
Richard L. Treanor, Ph.D.



Vincent K. Shier, Ph.D.
Registration No. 50,552

Customer Number

22850

Tel: (703) 413-3000
Fax: (703) 413-2220
(OSMMN 08/03)